Overview

NCI Definition: A carcinoma that arises from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree. Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas. Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats. Early detection is difficult and the prognosis is generally poor. [1]

Intrahepatic cholangiocarcinomas most frequently harbor alterations in IDH1, TP53, BAP1, FGFR2, and ARID1A [2].

Most Commonly Altered Genes in Intrahepatic Cholangiocarcinoma

IDH1 Mutation, IDH1 Codon 132 Missense, TP53 Mutation, IDH1 R132C, and BAP1 Mutation are the most common alterations in intrahepatic cholangiocarcinoma [2].

Top Alterations in Intrahepatic Cholangiocarcinoma

Significant Genes in Intrahepatic Cholangiocarcinoma

ERBB2 +

FGF1 +

FGF10 +

FGF11 +

FGF12 +

FGF13 +

FGF14 +

FGF16 +

FGF17 +

FGF18 +

FGF19 +

FGF2 +

FGF20 +

FGF21 +

FGF22 +

FGF23 +

FGF3 +

FGF4 +

FGF5 +

FGF6 +

FGF7 +

FGF8 +

FGF9 +

FGFR1 +

FGFR2 +

FGFR3 +

FGFR4 +

IDH1 +

Disease Details

Synonyms
ICC, Intrahepatic Bile Duct Carcinoma, CHOLANGIOCARCINOMA, INTRAHEPATIC, MALIGNANT, Intrahepatic Carcinoma of the Bile Duct, Intrahepatic Carcinoma of Bile Duct, Intrahepatic Cholangiocellular Carcinoma
Parent(s)
Liver and Intrahepatic Bile Duct Carcinoma
Children
Cholangiolocellular Carcinoma, Mucin-Producing Intrahepatic Cholangiocarcinoma, Sarcomatoid Intrahepatic Cholangiocarcinoma, Signet Ring Cell Intrahepatic Cholangiocarcinoma, and Perihilar Intrahepatic Cholangiocarcinoma
OncoTree Name
Intrahepatic Cholangiocarcinoma
OncoTree Code
IHCH

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.